{"id":"alectinib-usual","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Cough"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ALK is a type of enzyme that can be mutated and become overactive in certain cancers. Alectinib works by blocking the activity of the ALK protein, which can help slow or stop the growth of cancer cells.","oneSentence":"Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:53.760Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer with ALK rearrangement"},{"name":"Locally advanced or metastatic non-small cell lung cancer with ALK rearrangement"}]},"trialDetails":[{"nctId":"NCT05987956","phase":"PHASE2, PHASE3","title":"Pharmacogenomics ANDA 221517 SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2026-03-18","conditions":"Non-small Cell Lung Cancer","enrollment":600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Usual ALECENSA - alectinib hydrochloride capsule 600 mg orally twice daily"],"phase":"phase_2","status":"active","brandName":"Alectinib - Usual","genericName":"Alectinib - Usual","companyName":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","companyId":"han-xu-m-d-ph-d-fapcr-sponsor-investigator-irb-chair","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alectinib is an anaplastic lymphoma kinase (ALK) inhibitor that targets the ALK protein. Used for Metastatic non-small cell lung cancer with ALK rearrangement, Locally advanced or metastatic non-small cell lung cancer with ALK rearrangement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}